388 related articles for article (PubMed ID: 20104432)
1. Role of progesterone in endometrial cancer.
Kim JJ; Chapman-Davis E
Semin Reprod Med; 2010 Jan; 28(1):81-90. PubMed ID: 20104432
[TBL] [Abstract][Full Text] [Related]
2. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
3. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.
Dai D; Kumar NS; Wolf DM; Leslie KK
Am J Obstet Gynecol; 2001 Apr; 184(5):790-7. PubMed ID: 11303185
[TBL] [Abstract][Full Text] [Related]
4. Influence of AKT on progesterone action in endometrial diseases.
Lee II; Kim JJ
Biol Reprod; 2014 Sep; 91(3):63. PubMed ID: 25100707
[TBL] [Abstract][Full Text] [Related]
5. A functional role of LEFTY during progesterone therapy for endometrial carcinoma.
Fei W; Kijima D; Hashimoto M; Hashimura M; Oguri Y; Kajita S; Matsumoto T; Yokoi A; Saegusa M
Cell Commun Signal; 2017 Dec; 15(1):56. PubMed ID: 29268772
[TBL] [Abstract][Full Text] [Related]
6. Progesterone: the ultimate endometrial tumor suppressor.
Yang S; Thiel KW; Leslie KK
Trends Endocrinol Metab; 2011 Apr; 22(4):145-52. PubMed ID: 21353793
[TBL] [Abstract][Full Text] [Related]
7. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action.
Kumar NS; Richer J; Owen G; Litman E; Horwitz KB; Leslie KK
Cancer Res; 1998 May; 58(9):1860-5. PubMed ID: 9581825
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation and nuclear localization of beta-catenin in endometrial carcinoma in response to progesterone therapy.
Saegusa M; Hamano M; Kuwata T; Yoshida T; Hashimura M; Akino F; Watanabe J; Kuramoto H; Okayasu I
Cancer Sci; 2003 Jan; 94(1):103-11. PubMed ID: 12708483
[TBL] [Abstract][Full Text] [Related]
9. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
10. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.
Ando H; Miyamoto T; Kashima H; Higuchi S; Ida K; Mvunta DH; Shiozawa T
Horm Cancer; 2017 Aug; 8(4):257-267. PubMed ID: 28516379
[TBL] [Abstract][Full Text] [Related]
11. Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium.
Flannery CA; Fleming AG; Choe GH; Naqvi H; Zhang M; Sharma A; Taylor HS
Endocrinology; 2016 Oct; 157(10):3699-3708. PubMed ID: 27267714
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B.
Chi S; Liu Y; Zhou X; Feng D; Xiao X; Li W; Zhao Y; Wang H
Cancer Chemother Pharmacol; 2019 Feb; 83(2):277-287. PubMed ID: 30443761
[TBL] [Abstract][Full Text] [Related]
13. Progesterone receptor action in leiomyoma and endometrial cancer.
Kim JJ; Sefton EC; Bulun SE
Prog Mol Biol Transl Sci; 2009; 87():53-85. PubMed ID: 20374701
[TBL] [Abstract][Full Text] [Related]
14. Effects of hormone therapy on the endometrium.
Deligdisch L
Mod Pathol; 1993 Jan; 6(1):94-106. PubMed ID: 8426860
[TBL] [Abstract][Full Text] [Related]
15. Expression of uteroglobin in normal and carcinogenic endometrium and influence of hormone replacement therapy.
Tanaka R; Saito T; Shijubo N; Takehara M; Yamada G; Kawabata I; Itoh Y; Kudo R
Int J Cancer; 2004 Mar; 109(1):43-8. PubMed ID: 14735466
[TBL] [Abstract][Full Text] [Related]
16. Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen.
Elkas J; Armstrong A; Pohl J; Cuttitta F; MartÃnez A; Gray K
Obstet Gynecol; 2000 May; 95(5):697-703. PubMed ID: 10775732
[TBL] [Abstract][Full Text] [Related]
17. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
[TBL] [Abstract][Full Text] [Related]
18. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
[TBL] [Abstract][Full Text] [Related]
19. MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT.
Yoo JY; Kang HB; Broaddus RR; Risinger JI; Choi KC; Kim TH
BMC Cancer; 2018 May; 18(1):605. PubMed ID: 29843645
[TBL] [Abstract][Full Text] [Related]
20. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
